Nouscom

Switzerland
Breíl, Grisons, Switzerland, 4051

Company profile

Nouscom company profile

Nouscom is a developer of an immunotherapy platform that aims to create modified viral vector vaccines for cancer treatment. The company's platform makes use of a portfolio of engineered viral vectors that have been optimized for the efficient expression of long strings of tumor neoantigens. It also includes a toolkit for inducing broad and potent antitumor T-cell responses, allowing patients to boost cancer-specific cellular immunity.

Business identity

Contact email
[email protected]
Phone number
+41 612-01-18-31
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2015-01-01, Year

Headquarters

Postal code
4051
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Late Stage Venture
Funding rounds
4
Total equity funding
$143.4M
Last funding
Series C / $7.6M / 2024-03-21
Last equity funding
Series C / $7.6M
Investors
13
Lead investors
6
Founders
3
Articles
79

Founders and investors

Founders

Cinzia TraboniElisa ScarduelliRiccardo Cortese

Lead investors

AbingworthAndera PartnersAngelini VenturesBpifranceEQT Life SciencesM Ventures

Investors

5AM VenturesAbingworthAndera PartnersBpifranceEQT Life Sciences